Cerus (NASDAQ:CERS) reported earnings of ($0.10) per share beating Walls Streets expectations.

ME Staff
-
0

Cerus (NASDAQ:CERS) reported Q2 2018 earnings this Afternoon, coming in at ($0.10) per share, beating Wall Street’s estimates of ($0.11) per Share. Revenue for the quarter came in at $15.42 million beating analyst estimates of $13.58 million

Recent Insider Trading for Cerus (NASDAQ:CERS)

  • On 6/8/2018 Gail Schulze, Director, sold 52,500 with an average share price of $6.65 per share and the total transaction amounting to $349,125.00.
  • On 6/5/2018 Carol Moore, SVP, sold 75,000 with an average share price of $6.72 per share and the total transaction amounting to $504,000.00.
  • On 5/18/2018 Timothy B Anderson, Director, sold 23,000 with an average share price of $6.65 per share and the total transaction amounting to $152,950.00.
  • On 5/17/2018 Kevin Dennis Green, CFO, sold 73,000 with an average share price of $6.42 per share and the total transaction amounting to $468,660.00.
  • On 5/11/2018 Carol Moore, SVP, sold 60,841 with an average share price of $6.26 per share and the total transaction amounting to $380,864.66.
  • On 5/11/2018 Richard J. Benjamin, Insider, sold 8,631 with an average share price of $6.69 per share and the total transaction amounting to $57,741.39.



    About Company
    Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

    Recent Analyst Rating for Cerus (NASDAQ:CERS)



      Recent Trading for Cerus (NASDAQ:CERS)
      Shares of Cerus closed the previous trading session at with 7.46 shares trading hands.